Hospital
Fairview Hospital
Fairview Hospital was paid $17.67M by Medicaid between Jan 2018 and Dec 2024, across 163 billing codes. Its largest line is 99284, emergency room visit (serious) — 44% of everything it billed.
33Billing provider infoFAIRVIEW HOSPITAL
GREAT BARRINGTON, MA 01230
GREAT BARRINGTON, MA 01230
33aNPI1730112251assigned 07/08/2006
33bProvider typeCritical Access Hospital
28Total paid$17.67M
24GClaims277,471
24DCodes billed163
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Massachusetts
Rank by total paid#2 of 5
Median peer was paid$7.11M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RODOWICZ, DARLENE controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,295 | $2.24M | |
| 2019 | 37,174 | $2.09M | |
| 2020 | 32,808 | $1.70M | |
| 2021 | 42,743 | $2.60M | |
| 2022 | 45,528 | $3.15M | |
| 2023 | 47,993 | $3.41M | |
| 2024incomplete | 34,930 | $2.48M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 44% | 28,063 | 23,085 | $7.70M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.0% | 8,068 | 7,084 | $1.24M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.9% | 4,483 | 3,206 | $1.21M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.9% | 19,597 | 6,658 | $858K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.9% | 2,907 | 2,570 | $683K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 755 | 733 | $650K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.7% | 9,636 | 3,477 | $484K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.1% | 8,098 | 7,383 | $367K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 2,083 | 1,496 | $315K |
| 80053 | Comprehensive metabolic panel | 1.6% | 19,625 | 17,544 | $284K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 23,658 | 20,089 | $265K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.3% | 3,258 | 2,727 | $236K |
151 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 7,675 | $198K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 3,294 | $192K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.0% | 5,452 | $185K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,699 | $152K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,785 | $148K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,218 | $138K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,168 | $132K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 563 | $129K |
| 97161 | <1% | 813 | $122K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,066 | $120K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 447 | $114K |
| 80061 | Lipid panel | <1% | 6,787 | $113K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,957 | $113K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,143 | $97K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 328 | $89K |
| 86618 | <1% | 1,555 | $73K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 785 | $62K |
| 76376 | <1% | 5,685 | $54K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,521 | $51K |
| 84439 | <1% | 3,269 | $50K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,183 | $50K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 288 | $49K |
| 84703 | <1% | 2,491 | $47K | |
| 84484 | <1% | 2,913 | $45K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 905 | $43K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,121 | $37K |
| 82728 | <1% | 1,130 | $36K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 590 | $36K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 590 | $36K |
| 87088 | <1% | 3,158 | $33K | |
| 83690 | <1% | 2,677 | $32K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,833 | $28K |
| 86803 | <1% | 914 | $28K | |
| 81001 | <1% | 1,714 | $25K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 697 | $22K |
| 83735 | <1% | 2,724 | $21K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 74 | $20K |
| 76830 | Ultrasound, transvaginal | <1% | 95 | $19K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 26 | $18K |
| 87070 | <1% | 740 | $17K | |
| 84466 | <1% | 540 | $16K | |
| ATP14 | <1% | 6,656 | $16K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 388 | $16K |
| 73630 | <1% | 126 | $16K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 258 | $16K |
| 84182 | <1% | 297 | $15K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 98 | $15K |
| 81000 | <1% | 3,049 | $14K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,133 | $13K |
| 82607 | <1% | 341 | $13K | |
| 86141 | <1% | 863 | $13K | |
| 86140 | <1% | 721 | $10K | |
| 73610 | <1% | 72 | $10K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 101 | $9K |
| 59025 | Fetal non-stress test | <1% | 46 | $9K |
| 85610 | <1% | 4,090 | $8K | |
| 83540 | <1% | 594 | $8K | |
| 86666 | <1% | 71 | $8K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,440 | $8K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 376 | $8K |
| 71045 | Radiologic examination, chest; single view | <1% | 551 | $7K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,043 | $7K |
| 81003 | <1% | 802 | $7K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 200 | $7K |
| 85652 | <1% | 624 | $6K | |
| 86780 | <1% | 323 | $6K | |
| 0003A | <1% | 164 | $6K | |
| 81002 | <1% | 1,443 | $6K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 167 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,671 | $5K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 104 | $5K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 81 | $5K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 91 | $4K |
| 90686 | <1% | 277 | $4K | |
| 87340 | <1% | 249 | $4K | |
| ATP17 | <1% | 1,496 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,361 | $3K |
| 0002A | <1% | 57 | $3K | |
| 80076 | <1% | 325 | $3K | |
| 73562 | <1% | 25 | $3K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 68 | $3K |
| 83605 | <1% | 579 | $3K | |
| 87468 | <1% | 189 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 121 | $3K |
| 0001A | <1% | 45 | $3K | |
| 87469 | <1% | 178 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,347 | $2K |
| 85730 | <1% | 509 | $2K | |
| 86706 | <1% | 180 | $2K | |
| 87186 | <1% | 289 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 678 | $2K |
| ATP08 | <1% | 1,710 | $2K | |
| 97162 | <1% | 15 | $2K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 13 | $2K |
| 90715 | <1% | 29 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 45 | $2K |
| 83655 | <1% | 43 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 157 | $2K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 13 | $2K |
| 83880 | <1% | 185 | $1K | |
| 87631 | <1% | 35 | $1K | |
| 84702 | <1% | 29 | $1K | |
| 86704 | <1% | 122 | $1K | |
| 71271 | <1% | 12 | $1K | |
| ATP15 | <1% | 570 | $1K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 15 | $1K |
| 85027 | <1% | 109 | $1K | |
| 0124A | <1% | 32 | $1K | |
| 86709 | <1% | 147 | $934.84 | |
| 80164 | <1% | 244 | $897.93 | |
| 0013A | <1% | 15 | $866.83 | |
| 82077 | <1% | 30 | $840.95 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 275 | $746.26 |
| 97035 | <1% | 36 | $696.24 | |
| 0134A | <1% | 15 | $673.39 | |
| 81513 | <1% | 26 | $629.00 | |
| 85007 | <1% | 94 | $425.84 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 167 | $413.60 |
| 87486 | <1% | 13 | $398.86 | |
| 86850 | <1% | 14 | $355.55 | |
| 84100 | <1% | 148 | $344.62 | |
| 86769 | <1% | 13 | $252.78 | |
| 82570 | <1% | 16 | $222.78 | |
| 86901 | <1% | 15 | $209.76 | |
| 71250 | <1% | 24 | $209.71 | |
| 99406 | <1% | 26 | $194.49 | |
| 87634 | <1% | 16 | $192.09 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 14 | $167.83 |
| 86900 | <1% | 15 | $166.08 | |
| 86480 | <1% | 38 | $164.01 | |
| 87481 | <1% | 26 | $154.75 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 26 | $154.75 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 161 | $119.86 |
| 82962 | <1% | 36 | $99.23 | |
| 87040 | <1% | 39 | $95.85 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 12 | $70.06 |
| ATP03 | <1% | 12 | $61.65 | |
| ATP02 | <1% | 38 | $32.22 | |
| 84153 | <1% | 12 | $16.78 | |
| 84520 | <1% | 139 | $7.68 | |
| 82565 | <1% | 151 | $5.29 | |
| G0008 | Administration of influenza virus vaccine | <1% | 14 | $3.87 |
| 82248 | 0% | 29 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 52 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 60 | $0.00 |
| 91300 | 0% | 240 | $0.00 | |
| 91312 | 0% | 17 | $0.00 | |
| 84481 | 0% | 24 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 15 | $0.00 |
| 91313 | 0% | 15 | $0.00 | |
| 91301 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRODOWICZ, DARLENE (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Berkshire Medical Center, INC | Pittsfield, MA | $150.13M |
| Berkshire Medical Center, INC | Pittsfield, MA | $15.35M |
| Berkshire Faculty Services INC | Pittsfield, MA | $13.13M |
| Fairview Hospital | North Adams, MA | $3.50M |
| Berkshire Medical Center, INC. | Pittsfield, MA | $3.10M |
| Fairview Hospital | Williamstown, MA | $2.82M |
| Fairview Hospital | Great Barrington, MA | $1.95M |
| Berkshire Medical Center, INC | North Adams, MA | $639K |
| North Adams Regional Hospital Corporation | North Adams, MA | $306K |
| BHS Urgent Care Center | Pittsfield, MA | $126K |
| Berkshire Medical Center, INC. | Pittsfield, MA | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.